Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Clinical Study Site, Tucson, Arizona +166 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Jonesboro, Arkansas +225 locations
Conditions: Neoplasms, Head and Neck
Register for Updates
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333
Recruiting
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Cardiology P.C. Birmingham, Birmingham, Alabama +45 locations
Conditions: Congestive Heart Failure
Register for Updates
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118
Recruiting
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/28/2025
Locations: Research Site, Birmingham, Alabama +63 locations
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Register for Updates
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132
Recruiting
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
05/28/2025
Locations: Mission dermatology Center, Rancho Santa Margarita, California +34 locations
Conditions: Generalized Epidermolysis Bullosa Simplex
Register for Updates
Selecting Hypoxic Tumours for Treatment Modification
NCT06787053
Recruiting
Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (\>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensification. Treatment intensification can be modification with CON (breathing O2-enriched air + oral administration of nicotinamide), chemoradiosensitisation, radiation dose-escalation or additional systemic treatments, signi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: The Christie NHS Foundation Trust, Manchester, Not set
Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
Register for Updates
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/28/2025
Locations: University of Florida Clinical Research Center, Gainesville, Florida +15 locations
Conditions: Glycogen Storage Disease Type II Infantile Onset
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
05/27/2025
Locations: Cenexel, Englewood, Colorado +38 locations
Conditions: Huntington's Disease
Register for Updates
User Evaluation of a Home-collection Kit for People With Diabetes
NCT06038669
Recruiting
Type 1 and Type 2 are the most common types of diabetes mellitus. Although the cause of Type 1 is different to Type 2, they can both lead to high blood glucose levels as the patient is unable to store and use sugar. The disease is an epidemic of the 21st century which is increasing, having a current prevalence of approximately 8%. Poor disease control is associated with a range of long-term health conditions which have a severe impact upon quality of life and are responsible for the increased m... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/27/2025
Locations: University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Not set
Conditions: Diabetes
Register for Updates
Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom
NCT03039309
Recruiting
Multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Portsmputh Hospitals NHS Trust, Portsmouth, Not set
Conditions: Endoscopic Submucosal Dissection
Register for Updates
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
NCT06223893
Recruiting
The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management with current standard of care in these patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Not set +14 locations
Conditions: Decompensated Cirrhosis
Register for Updates
Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal
NCT06997874
Recruiting
Background and study aims The retina is the layer at the back of the eye that allows us to see. Sometimes, it can detach from the wall of the eye, causing a condition called rhegmatogenous retinal detachment (RRD), which leads to vision loss and requires surgery. The most common surgery for RRD is vitrectomy, but this can lead to complications like cataracts, which worsen over time and need to be removed with another surgery. Cataract surgery involves replacing the cloudy lens with a clear artif... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Buckinghamshire Healthcare NHS Trust, Aylesbury, Not set +26 locations
Conditions: Rhegmatogenous Retinal Detachment
Register for Updates